Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.

Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC

Avutometinib plus abemaciclib and fulvestrant had manageable toxicity in CDK4/6-resistant, HR+/HER2– metastatic breast cancer.

Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer

A phase 1b trial examining SYN818 plus olaparib in patients with solid tumors will be conducted in the second half of 2025.

SYN818 Shows Favorable Safety Profile in Locally Advanced or Metastatic Solid Tumors

Runimotamab in combination with trastuzumab led to clinical activity and tolerability vs runimotamab alone in HER2-positive breast cancer.

Runimotamab Plus Trastuzumab Is Active and Tolerable in HER2+ Breast Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

Interactive Tools

Biomarker Consortium

Subscribe

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Patients with myelofibrosis who initiated ruxolitinib within 2 years of diagnosis achieved higher spleen response rates vs those with delayed initiation.  

Early Ruxolitinib Initiation Increases Spleen Response Rates in Myelofibrosis 

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Adam Calaway, MD, MPH, highlights the need for early detection and education in testicular cancer. 

Testicular Cancer Awareness Month: Early Detection and Risk Assessment Pave the Way Toward Optimal Outcomes

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types. 

Cancer Vaccines Begin to Take Center Stage With Investigators Anticipating an Even Brighter Future

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

CME Opportunities

Specialty

OncLive Peer Exchange®

Practical Perspectives on Acute Lymphocytic Leukemia

Videos

Acute Lymphoblastic Leukemia: Risk Stratification

T-Cell Acute Lymphoblastic Leukemia: Impacting Prognosis 

Philadelphia Chromosome-Positive ALL: Upfront Approaches 

Defining Ponatinib's Role in Ph-Positive ALL

Up-front Approaches to Treating Ph-Negative ALL 

Optimizing Allogeneic Transplant Strategies in ALL

Importance of MRD Testing in Acute Lymphoblastic Leukemia 

MRD Testing in ALL: Sensitivity and Availability 

Acute Lymphoblastic Leukemia: Challenges in MRD Testing 

Acute Lymphoblastic Leukemia: Optimizing MRD Testing 

ALL: Therapy for Post-Induction MRD-Positivity 

MRD-Positive ALL: Personal Approaches to Treatment   

Approaching Treatment for Relapsed/Refractory ALL 

Relapsed/Refractory ALL: Evaluating Novel Agents   

Relapsed/Refractory ALL: Inotuzumab Ozogamicin 

Role of CAR T-Cell Therapy in Relapsed/Refractory ALL 

Acute Lymphoblastic Leukemia: The Future of Treatment 

Practical Perspectives on Acute Lymphocytic Leukemia

Latest Conference Coverage